Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
N Engl J Med, 2016
Liraglutide reduced major adverse cardiovascular events by 13% vs placebo in type 2 diabetes patients at high cardiovascular risk
Content reviewed by clinical research staff
Evidence graded using the PeptideScholar A-D system.
Liraglutide
AFDA Approved
90
Excellent Credibility
FDA ApprovedPrescription Required
Liraglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Victoza) and chronic weight management (Saxenda). It was the first GLP-1 agonist approved specifically for obesity.
Mechanism of Action
Mimics endogenous GLP-1, activating GLP-1 receptors to enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite through hypothalamic signaling. Has 97% amino acid sequence homology with human GLP-1.
Benefits
This content is for informational purposes only and does not constitute medical advice.
Liraglutide - Dosing in Published Research
Reported routes: Subcutaneous injection
Victoza: titrated from 0.6 mg to 1.2-1.8 mg SC daily. Saxenda: titrated from 0.6 mg to 3.0 mg SC daily over 5 weeks.
The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.
Side Effects
Discuss Liraglutide with a doctor
Liraglutide is FDA-approved and available by prescription. Licensed telehealth providers can evaluate if it's right for you.
Get the Provider ChecklistStart with the evidence and provider checklist while routing is offline.
FDA approvedBoard-certified doctorsPrescription if appropriate
PeptideScholar may receive compensation from provider referrals. This does not influence our editorial content.
Approved Treatment Routing
Liraglutide in PeptideScholar's approved-treatment dataset
Liraglutide is currently modeled on this site as an approved treatment path for: Type 2 diabetes mellitus (Victoza); chronic weight management in adults with BMI ≥30 or ≥27 with comorbidities (Saxenda). Brand names in the current dataset: Victoza, Saxenda.
Validation note: This block reflects the site's current structured treatment data and internal routing logic. It is not a substitute for checking current prescribing, labeling, payer, or local regulatory details.
Treatment Hub
Liraglutide Treatment Guide
Approved product paths, real cost friction, provider routing, and tracker next steps — all in one source-backed hub.
Open treatment hub →Research & Evidence
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
N Engl J Med, 2015
Liraglutide 3.0 mg produced 8.0% mean body weight loss vs 2.6% with placebo over 56 weeks in 3,731 adults
Compare Liraglutide With
References
- 1.Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.. N Engl J Med, 2016. "Liraglutide reduced major adverse cardiovascular events by 13% vs placebo in type 2 diabetes patients at high cardiovascular risk" [PMID: 27295427]
- 2.A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.. N Engl J Med, 2015. "Liraglutide 3.0 mg produced 8.0% mean body weight loss vs 2.6% with placebo over 56 weeks in 3,731 adults" [PMID: 26132939]
Recommended Resources
The Peptide Protocols Handbook
Evidence-based reference guide covering mechanisms, research, and clinical applications.
View on AmazonThird-Party Peptide Testing
Independent lab analysis to verify peptide purity and authenticity.
Learn MoreLinks may be affiliate links. See our disclosure.
GLP-1 Support Essentials
Products to help manage side effects and optimize outcomes during treatment.
LMNT Electrolyte Packets
Sodium-focused electrolytes to prevent dehydration and fatigue common in early GLP-1 therapy.
$30–45View on Amazon
High-Protein Shakes (30g)
Convenient protein shakes to maintain muscle mass on reduced GLP-1 caloric intake.
$28–42View on Amazon
Metamucil Fiber Supplement
Soluble fiber powder to manage constipation and GI side effects during GLP-1 treatment.
$20–30View on Amazon
Vitamin B12 (Methylcobalamin 1000mcg)
GLP-1 agonists can reduce B12 absorption over time — methylcobalamin is the most bioavailable form.
$10–20View on Amazon
Ginger Chews for Nausea
Natural nausea relief for the dose-escalation adjustment period, particularly weeks 1–4.
$8–15View on Amazon
Unflavored Whey Protein Isolate
Preserve lean mass without excess carbs or calories when appetite is suppressed.
$35–60View on Amazon
Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.
Progress Tracking Tools
Monitor weight, body composition, and nutrition to maximize results.
Smart WiFi Body Scale
Tracks BMI, body fat %, and muscle mass — essential for monitoring GLP-1 progress over time.
$30–60View on Amazon
Digital Kitchen Food Scale
Precise gram-level portion tracking helps maximize weight loss results on GLP-1 therapy.
$10–20View on Amazon
Protein Shaker Bottle Set
Leak-proof mixing bottles for protein shakes — supports consistent protein intake on a smaller appetite.
$12–25View on Amazon
Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.
Recommended Reading
Books covering peptide science, longevity research, and biohacking frameworks.
The Peptide Protocols
Comprehensive reference for peptide mechanisms, dosing research, and clinical applications.
$20–35View on Amazon
Boundless by Ben Greenfield
Covers peptides, nootropics, hormones, and longevity strategies in an optimization framework.
$25–40View on Amazon
Lifespan by David Sinclair
Evidence-based deep-dive into aging science, directly relevant to longevity peptide research.
$15–28View on Amazon
The Longevity Paradox
Gut-centric aging research with diet and supplementation protocols for extending healthspan.
$15–28View on Amazon
Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.
Liraglutide FAQ
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.